Outlook Therapeutics (OTLK) Tax Provisions (2015 - 2025)
Outlook Therapeutics (OTLK) reported Tax Provisions of -$1.6 million for Q3 2025, down 55622.46% quarter-over-quarter from $2800.0 in Q1 2025.
Outlook Therapeutics (OTLK) Tax Provisions (2015 - 2025) Analysis & Trends
Outlook Therapeutics (OTLK) has 11 years of Tax Provisions data on file, last reported at -$1.6 million in Q3 2025.
- Tax Provisions for Q3 2025 came in at -$1.6 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was -$1.6 million (down 55522.46% YoY), and the FY2025 annual result was -$1.6 million, down 55522.46% from the prior year.
- Tax Provisions slipped to -$1.6 million in Q3 2025 per OTLK's latest filing, from $2800.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $2800.0 in Q1 2023 and troughed at -$1.6 million in Q3 2025.
- A 5-year average of -$220204.1 and a median of $2000.0 in 2021 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2022 and 2023: Tax Provisions changed 0.0% in 2022, then soared 40.0% in 2023.
- A 5-year view of Tax Provisions shows it stood at $2000.0 in 2021, then sank by 60.0% to $800.0 in 2022, then soared by 250.0% to $2800.0 in 2023, then changed by 0.0% to $2800.0 in 2024, then tumbled by 55622.46% to -$1.6 million in 2025.
- Business Quant data shows OTLK's Tax Provisions at -$1.6 million in Q3 2025, $2800.0 in Q1 2025, and $2800.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -859,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 216,000.00 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.55 Mn |
| Mar 31, 2025 | 2,800.00 |
| Mar 31, 2024 | 2,800.00 |
| Mar 31, 2023 | 2,800.00 |
| Sep 30, 2022 | 800.00 |
| Mar 31, 2022 | 2,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Sep 30, 2020 | -805.00 |
| Jun 30, 2020 | -3.27 Mn |
| Sep 30, 2019 | -2.63 Mn |
| Jun 30, 2019 | -777,500.00 |
| Sep 30, 2018 | -497,500.00 |
| Dec 31, 2017 | -3.15 Mn |
| Sep 30, 2017 | 398,500.00 |
| Dec 31, 2016 | 4,000.00 |
| Jun 30, 2016 | 500.00 |
| Mar 31, 2016 | 50,500.00 |
| Dec 31, 2015 | 52,000.00 |
| Sep 30, 2015 | 9,744.00 |
| Jun 30, 2015 | 120,000.00 |